EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trimethylamine N-Oxide (TMAO) Plasma Levels in Patients with Different Stages of Chronic Kidney Disease

Marcia Ribeiro, Julie Ann Kemp, Ludmila Cardozo iD, Drielly Vargas, Marcelo Ribeiro-Alves iD, Peter Stenvinkel iD, Denise Mafra iD

Toxins · 31.12.2024 · 17 (1) · 15

DOI: 10.3390/toxins17010015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, online erschienen am 31.12.2024. Verfasst von Marcia Ribeiro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Biological Sciences-Physiology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-630, Brazil. Hauptthemen laut MEDLINE: Methylamines, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with chronic kidney disease (CKD), trimethylamine n-oxide (TMAO) accumulation exacerbates inflammation and contributes to oxidative stress. These complications are putatively linked to the development of cardiovascular diseases. Despite the known associations, the variation in TMAO plasma levels across different CKD stages and dialysis modalities remains underexplored. This study aimed to quantify TMAO plasma levels in different CKD stages and dialysis treatments.

Methods

This cross-sectional study assessed TMAO plasma levels in non-dialysis CKD patients (ND), patients undergoing hemodialysis (HD), and peritoneal dialysis (PD). TMAO plasma levels were assessed by liquid chromatography coupled to triple mass spectrometry quadrupole.

Results

In total, 15 ND patients [stages 3–5, glomerular filtration rate 41.4 mL/min/1.73 m2, 64 (IQR = 12.5) years, BMI 25.2 kg/m2, eight women]; 14 PD patients [57.5 (IQR = 8.5) years, BMI of 27.8 kg/m2, nine women]; and 34 HD patients [43.5 (IQR = 45.5) years, BMI of 24.4 kg/m2, nineteen women] were analyzed. ND patients had lower TMAO levels when compared to the HD (p < 0.0001) and PD patients (p = 0.001). There was no difference in TMAO levels between patients undergoing dialysis (p < 0.59). There was a negative correlation between TMAO and HDL plasma levels [rho = −0.380 (p < 0.004)], calcium [rho = −0.321 (p < 0.016)], and albumin [rho = −0.416 (p < 0.001)]. In addition, a positive correlation between TMAO and urea levels was observed [rho = 0.717 (p < 0.001)].

Conclusions

CKD stages impact TMAO levels since patients on non-dialysis treatment had lower levels than patients on HD and PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethylaminesRenal Insufficiency, ChronicHumansFemaleMaleMiddle AgedCross-Sectional StudiesRenal DialysisAdultAgedPeritoneal Dialysis

Stichwörter der Autor:innen

chronic kidney diseasedialysistrimethylamine N-oxideuremic toxins

Substanzen

Methylaminestrimethyloxamine

Autor:innen und Institutionen

  • Graduate Program in Biological Sciences-Physiology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-630, Brazil.
  • Graduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Niterói 24220-900, Brazil.
  • Division of Nephrology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-630, Brazil.
  • HIV/AIDS Clinical Research Center, National Institute of Infectology (INI/Fiocruz), Rio de Janeiro 21040-360, Brazil.
  • Division of Renal Medicine, Department of Clinical Science, Technology, and Intervention, Karolinska Institute, 141-86 Stockholm, Sweden.

ORCID-Profile: Ludmila Cardozo, Marcelo Ribeiro-Alves, Peter Stenvinkel, Denise Mafra

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
  • Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)

Zitieren

APA

Ribeiro, M., Kemp, J. A., Cardozo, L., Vargas, D., Ribeiro-Alves, M., Stenvinkel, P., & Mafra, D. (2024). Trimethylamine N-Oxide (TMAO) Plasma Levels in Patients with Different Stages of Chronic Kidney Disease. Toxins, 17(1), 15. https://doi.org/10.3390/toxins17010015

Vancouver

Ribeiro M, Kemp JA, Cardozo L, Vargas D, Ribeiro-Alves M, Stenvinkel P, et al. Trimethylamine N-Oxide (TMAO) Plasma Levels in Patients with Different Stages of Chronic Kidney Disease. Toxins. 2024;17(1):15. doi:10.3390/toxins17010015

BibTeX
@article{Ribeiro2024,
  author = {Ribeiro, Marcia and Kemp, Julie Ann and Cardozo, Ludmila and Vargas, Drielly and Ribeiro-Alves, Marcelo and Stenvinkel, Peter and Mafra, Denise},
  title = {Trimethylamine N-Oxide (TMAO) Plasma Levels in Patients with Different Stages of Chronic Kidney Disease},
  journal = {Toxins},
  year = {2024},
  volume = {17},
  number = {1},
  pages = {15},
  doi = {10.3390/toxins17010015}
}
Kostenlos starten →